Wenning Qin, PhD (she/her/hers)

eGenesis, John McNeish Memorial Lecture, United States

Dr. Wenning Qin is Senior Vice President, Innovation, at eGenesis. She has over 20 years of experience in gene editing in multiple species. She earned a B.S. in Public Health and an M.S. in cardiovascular physiology from Tongji Medical University (Wuhan, China), and a Ph.D. in cardiovascular pharmacology from Southern Illinois University (Carbondale, IL.). Her postdoctoral training was in transcriptional regulation of gene expression from Washington University School of Medicine (St. Louis, MO). Her previous professional associations included Monsanto Life Sciences, Pharmacia Corporation, Pfizer Inc., Biogen Idec, and the Jackson Laboratory. In current role with eGenesis, Dr. Qin is responsible for porcine genome engineering strategies and execution, aspiring to bringing porcine cells, tissues, and organs to clinical practice and transforming the treatment of organ failure.

Presentation(s):

• PLENARY IV: STEM CELLS FOR HUMAN THERAPY

  Saturday, June 14, 2025
  9:30 AM – 11:00 AM HK Time

• REVOLUTIONIZING THE TREATMENT OF ORGAN FAILURE

  Saturday, June 14, 2025
  10:35 AM – 10:55 AM HK Time